- Home
- SNTI vs CRDL Comparison
SNTI vs CRDL Comparison
Compare SNTI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CRDL
- Stock Information
- Founded
- SNTI 2016
- CRDL 2017
- Country
- SNTI United States
- CRDL Canada
- Employees
- SNTI N/A
- CRDL N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNTI Health Care
- CRDL Health Care
- Exchange
- SNTI Nasdaq
- CRDL Nasdaq
- Market Cap
- SNTI 85.3M
- CRDL 80.1M
- IPO Year
- SNTI N/A
- CRDL N/A
- Fundamental
- Price
- SNTI $3.10
- CRDL $1.15
- Analyst Decision
- SNTI Strong Buy
- CRDL Strong Buy
- Analyst Count
- SNTI 1
- CRDL 3
- Target Price
- SNTI $12.00
- CRDL $9.00
- AVG Volume (30 Days)
- SNTI 225.5K
- CRDL 150.5K
- Earning Date
- SNTI 05-06-2025
- CRDL 05-20-2025
- Dividend Yield
- SNTI N/A
- CRDL N/A
- EPS Growth
- SNTI N/A
- CRDL N/A
- EPS
- SNTI N/A
- CRDL N/A
- Revenue
- SNTI N/A
- CRDL N/A
- Revenue This Year
- SNTI N/A
- CRDL N/A
- Revenue Next Year
- SNTI N/A
- CRDL N/A
- P/E Ratio
- SNTI N/A
- CRDL N/A
- Revenue Growth
- SNTI N/A
- CRDL N/A
- 52 Week Low
- SNTI $1.52
- CRDL $0.77
- 52 Week High
- SNTI $16.94
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- SNTI 41.06
- CRDL 57.19
- Support Level
- SNTI $3.10
- CRDL $1.02
- Resistance Level
- SNTI $3.61
- CRDL $1.19
- Average True Range (ATR)
- SNTI 0.40
- CRDL 0.07
- MACD
- SNTI -0.07
- CRDL 0.01
- Stochastic Oscillator
- SNTI 9.50
- CRDL 73.53
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.